AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals, Reuters reports. Rhythm’s latest results show the attraction of its rare-obesity franchise, but milestone payments complicate the headline price.
Part of a broader series of DaaS contract opportunities currently under negotiation; Company targets profit margins of 40%–60% through drone integration and proprietary AI data analytic software processing VANCOUVER, British Columbia, Nov.
Google credit support strengthens TeraWulf’s ability to secure competitive project financing for contracted AI infrastructure at Hawesville, Kentucky campus Fluor agreement expands engineering and construction capacity, with defined delivery milestones EASTON, Md.,
– Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model – Phase
Webinar will be held on November 5, 2026, at 11:00 AM Eastern Time NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal enhanced potency and specificity
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular profiling
Following $1.03 million in completed annualized cost reductions, Polar targets approximately $2 million in total annualized savings, inclusive of Phase 1 of its Restructuring, while positioning operations to support scalable revenue growth
Follow